Two of the best performers in the past five trading days are not typical Singapore stocks: JMH is quoted in US dollars and AvePoint is also listed in the United States. Iggy and Angela ask what the currency and the second listing change for a Singapore investor, and what stays the same.
Two of last week’s biggest SGX movers were not ordinary Singapore stocks. JMH is quoted in US dollars, while AvePoint is also listed in the United States, so the price board is only the start of the story. I walk through how currency conversion can turn a five percent gain into almost nothing in Singapore dollars, and why a dual listing can change where results and announcements appear. Before you react to any weekly percentage, check the currency, the listing and what the table leaves out.
Key takeaways:
JMH’s SGX line is quoted in US dollars, not Singapore dollars.
A five percent USD gain can become almost no gain after the exchange rate moves.
AvePoint has a United States listing and a Singapore listing, so check where its filings appear.
The weekly table covers companies above a one billion dollar market value, not the whole market.
Iggy’s Forensic Disclaimer
This content is produced for educational and informational purposes only. I am not a financial advisor. I am a retail investor who applies forensic analysis to my own portfolio and shares that process publicly. Nothing here constitutes a recommendation to buy, sell, or hold any security, and no specific target prices or personalised financial advice are offered.
Stocks assessed under Iggy’s Forensic Yield Standard are benchmarked against a 4.7% minimum yield hurdle. Stocks flagged as Growth Watch fall below this threshold but demonstrate clean balance sheet metrics and an identifiable growth catalyst. These carry a materially different risk profile and are not suitable as yield replacements for income-dependent investors.
All data is sourced from public filings and verified sources. Where data is unverified, it is explicitly flagged. All investments carry risk, including the potential loss of principal, and past performance is not indicative of future results. If you are making investment decisions involving CPF, SRS, or personal capital, please conduct your own due diligence or consult a MAS-licensed financial adviser before committing funds.
